TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age between 35 and 41 weeks of gestation~* \< 24 hours of life~* Nasal Continuous Positive Airways Pressure (nCPAP) for more than 1 hour~* FiO2 ≥ 30% with nCPAP and a target post-ductus arteriosus SpO2 \>92%~* Written consent of the parents~Exclusion Criteria:~* FiO2 \> 60% with nCPAP, ou FiO2 \> 40% for 3 consecutives hours whatever the respiratory support~* Life threatening congenital pathology~* Congenital cardiopathy (except patent ductus arteriosus)~* Shock defined as systemic hypotension (mean blood pressure \<10th percentile of the normal range for birth weight and postnatal age) with at least 3 of the following criteria for decrease perfusion: 1) tachycardia (heart rate \> 160 beats/min); 2) abnormal peripheral pulses; 3) modified extremities coloration; 4) prolonged capillary refill time \> 3 seconds; 5) urine output \< 1 ml/kg/h~* Blood gas pH \< 7.19 and / or PCO2 \> 65 mmHg~* Apgar score ≤ 3 at 5 minutes of life

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Month
- Healthy Volunteers: f

Study Arms:
- Early strategy (Type: EXPERIMENTAL): Intratracheal poractant alpha (Curosurf®) after tracheal intubation
- Delayed strategy (Type: ACTIVE_COMPARATOR): Nasal Continous Positive Airways Pressure. Intratracheal poractant alpha as a rescue treatment if FiO2 \> 60%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent Form signed~* Adequate Performance status (ECOG 0-1)~* Female patients with unifocal breast tumors (stages II-III, TN, HER2+ or Luminal B) very sensitive to neoadjuvant medical treatment (5 to 6 months in accordance with the current standard)~* Patients who submit clinical-radiologic greater response to the treatment administered (equal to or less than 1.5 cm in NMR residual tumor)~Exclusion Criteria:~* Ki67\<14%~* Excisional biopsy Contraindications

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Breast tumors sensitive to neoadjuvant (Type: None): Treated patients as usual clinical practice with unicentered tumors in stages II or III and good response determined by MR after 6 cycles of treatment (less than 2 cm apparent residual injury) will be consecutively subjected to radiofrequency biopsy and the surgery previously established for each case (Tumorectomy or mastectomy). Before surgery, the sentinel node will be biopsied in order to define the surgical treatment on the axilla (none in case of negative sentinel node, axillary lymphadenectomy if positive).~The tumor samples obtained by percutaneous radiofrequency and mastectomy-Tumorectomy biopsy will be studied thoroughly to define the correlation between the two.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Targeting ER Stress in Vascular Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Young, healthy weight adults (age: 18-35; BMI 18.5-24.9 kg/m2)~* Young, obese adults (age: 18-35; BMI 30- 39.9 kg/m2)~* Older, healthy weight adults (age: 60-80; 18.5-24.9 kg/m2)~* Older, obese adults (age: 60-80; 30-39.9 kg/m2)~Exclusion Criteria:~* blood pressure \>140/90 mmHg~* triglycerides \>500 mg/dL or LDL cholesterol \>190 mg/dL~* current smoking or history of smoking in the last 12 months~* diagnosed chronic disease including cancer, cardiovascular, diabetes, kidney, liver, and pancreatic disease~* weight change \>3 kg in the past 3 months or actively trying to lose weight~* \>12 alcoholic drinks/week~* hormone replacement therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- TUDCA (Type: EXPERIMENTAL): Young and older healthy weight and obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive 1750 mg/day of the dietary supplement tauroursodeoxycholic acid (TUDCA) for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
- Placebo (Type: PLACEBO_COMPARATOR): Older obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive oral capsules containing a placebo treatment for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Cryopreserved Blastocyst's ImplantatiOn Potential After Genetic Screening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 2 blastocysts suitable for biopsy on day 5 of embryo development remaining after fresh transfer~* willing and able to give informed consent~* infertility as an indication for IVF/ICSI~* first or second IVF/ICSI cycle~* patients willing to accept single embryo transfer~* BMI range 18 to 35 kg/m2~Exclusion Criteria:~* any type of genetic abnormality or family history of genetic abnormality in subject or partner~* any other non-study related preimplantation genetic testing~* three or more clinical miscarriages (recurrent pregnancy loss, RPL)~* recurrent implantation failure (RIF): no positive β-hCG after transfer (fresh IVF/ICSI cycle or frozen) with no less than 6 cleavage stage embryos or no less than 4 blastocysts, all of good quality and of appropriate developmental stage~* severe endometriosis~* abnormal uterine cavity~* cycles requiring surgical sperm recovery procedures, total asthenozoospermia and/or globozoospermia~* treatment involving use of donor oocytes or use of gestational carrier

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- PGS (genetic screening) (Type: EXPERIMENTAL): Intent to transfer single cryopreserved embryo, selection based on euploid status (after preimplantation genetic screening) and standard morphological assessment
- no PGS (no genetic screening) (Type: NO_INTERVENTION): Intent to transfer single cryopreserved embryo, selection based on standard morphological assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Non-invasive Ventilation on Rehabilitation Outcome in COPD-patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of COPD in stages GOLD III/ IV~* receiving optimized medical treatment and long term oxygen therapy if needed~* patients consent to participate in this trial~* no treatment with NIV in the last 4 weeks~* treatment with NIV in the last 4 weeks due to an acute exacerbation~Exclusion Criteria:~* treatment with NIV in the last 4 weeks (except due to an acute exacerbation)~* Intolerance to perform NIV~* Acute exacerbation at baseline or during PR~* Hypercapnia \> pCO2 55mmHg~* Inability to perform a 6 minute walking test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- pulmonary rehabilitation with NIV (Type: ACTIVE_COMPARATOR): Patients receiving nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
- pulmonary rehabilitation without NIV (Type: SHAM_COMPARATOR): Patients receiving no nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 50+ years of age~* Clinical suspicion for prostate cancer~* Elevated Prostate-specific Antigen between 2.0-10 ng/ mL~* At least one (1) prior negative prostate biopsy~Exclusion Criteria:~* Use of medications or hormones that are known to affect serum PSA levels within 3-6 months of study enrollment including 5-alpha-reductase inhibitors used in the treatment of an enlarged prostate gland (benign prostatic hyperplasia). Drugs in this class are finasteride (Proscar, Propecia) and dutasteride (Avodart).~* Clinical symptoms of urinary tract infection (including prostatitis) at the time of enrollment.~* History of prostate cancer.~* History of invasive treatments for benign prostatic hypertrophy (BPH) or lower urinary track symptoms within 6 months of study enrollment.~* No known hepatitis status (all types) and/or HIV documented in patient's medical record.~* Patients with history of concurrent renal/bladder tumors.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Toe Flexion Training Protocol on Older Adults' Mobility

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 60 and 85 completed years;~* To be male or female;~* To be in good health meaning to be in a complete state of physical, mental and social well-being with the absence of pathologies, pain or complaints to the lower limbs,~* Be affiliated or beneficiary of a social security insurance;~* Having freely given their written consent after having been informed of the purpose, the procedure and the potential risks involved.~Exclusion Criteria:~* Use of pharmacological therapy to match gander identity; Have a major comorbidity corresponding to a score \>4 points on the Charlson Comorbidity Index (French Version);~* Score \<24 points in the MMSE-Fr;~* Have spasticity or severe cerebellar ataxia in the leg;~* Have an abnormal range of motion of the toes and/or ankle;~* Have a neurological or vestibular deficit that may affect walking or balance (lumbar-sacral radiculopathy, peripheral nerve pathology, Marfan or Eehlers-Danlos syndrome, etc.);~* Have a musculoskeletal injury that impairs walking or balance;~* Have a high resting heart rate (\> 90 beats per minute) and blood pressure \> 144/94 mmHg;~* Have a history of illness or conditions that would compromise the safety of the participant during the study;~* Participate at the same time in another medical interventional experiment or have participated in such a study in the 30 days preceding this study;~* Being unable to understand the purpose and conditions of the study, and to give consent;~* Being deprived of liberty or under guardianship.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Training group (Type: EXPERIMENTAL): Participants benefit from an 8-week training program of muscle strengthening
- Control group (Type: SHAM_COMPARATOR): Participants in the control group will be asked to maintain their habits and lifestyle (without training program) for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Functional Imaging of Psychic Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Non specific criteria, for all the participants:~* Woman- 18-50 years old~* Non menopausal~* Right-handed~* Caucasian from western Europe (exception of Basque and Sardinian), for genetic purposes~* Subject who signed informed consent~* Able to understand the nature, the aim, and the methodology of the study and agree to cooperate during clinical and radiological evaluation~Specific criteria:For depressed suicide attempters :~* DSM IV criteria for major depressive disorder~* Personal history of suicide attempt~* No psychotropic treatment currently~For depressed affective controls :~* DSM IV criteria for major depressive disorder~* No personal history of suicide attempt~* No psychotropic treatment currently~For non depressed suicide attempters :~* Personal history of unipolar or bipolar mood disorder, according to DSM IV criteria~* Normothymic currently (HAMD\<7)~* Personal history of suicide attempt~* Minimum treatment Healthy controls :~* No personal history of axis I psychiatric disorders according to the MINI and the DSM IV criteria

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: EXPERIMENTAL): None
- Depressive attempters (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed ovarian cancer~* Stage IIIB/IV~* Failure to prior chemotherapy with paclitaxel /carboplatin regimen and treatment free interval \> 6 months~* Presence of two-dimensional measurable disease.~* Life expectancy of more than 3 months.~* Age ≥ 18 years.~* Performance status (WHO) 0-2~* Adequate bone marrow function (Absolute neutrophil count \>1000/mm\^3, Platelet count\>100000/mm\^3, Hemoglobin\>9gr/mm\^3)~* Adequate liver (Bilirubin\<1.5 times upper limit of normal and SGOT/SGPT\<2 times upper limit of normal) and renal function (creatinine\<2mg/dl)~* Informed consent~Exclusion Criteria:~* Pregnant or nursing~* Psychiatric illness or social situation that would preclude study compliance'~* Other concurrent uncontrolled illness~* Other invasive malignancy within the past 5 years except nonmelanoma skin cancer~* Other concurrent investigational agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Docetaxel/carboplatin
- 2 (Type: EXPERIMENTAL): Docetaxel/Caelyx

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with soft tissue sarcoma treated with chemotherapy form 2004 and 2005.~Exclusion Criteria:~* Not Specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chart Review (Type: None): patients diagnosed with soft tissue sarcoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post Market Study for FloShield 10mm Reusable Cannula and Blunt Obturator and Robotic FloShield

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years or older~* Scheduled for a laparoscopic single-incision surgery for cholecystectomy, benign hysterectomy or salpingo-oophorectomy under the care of the study investigator~* Suitable candidate for surgery~* Is able to read and understand the informed consent form and has voluntarily provided written informed consent~Exclusion Criteria:~* Unfit for surgery: concomitant disorders incompatible with the study or surgery (at the discretion of the investigator)~* Subjects with known allergy (hypersensitivity) to Docusate Sodium~* Use of Surgiquest AirSeal during the laparoscopic single-site surgery~* Use of humidified insufflation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10mm Cannula (Type: None): Subjects that are scheduled for a robot-assisted laparoscopic single-incision surgery for cholecystectomy, benign hysterectomy or salpingo-oophorectomy under the care of the study investigator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Proximal Caries Infiltration and Detection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6-13 years~* Early caries lesions in primary molars (depth: E1 or E2)~* Good general health~* Available for 12 \& 24 months recalls~* Signed consent/assent/HIPAA~Criteria used to assess teeth for acceptance into this study:~* Teeth fully erupted, in functional occlusion and~* Radiographic evidence of early caries in interproximal areas~Exclusion Criteria:~* Participation in other study~* History of adverse reaction on clinical material~* Sensitivity during screening test~* Poor access to teeth~* Patient refusing radiographic examination

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Resin infiltration (Type: EXPERIMENTAL): Enrolled proximal early caries lesions will be treated using the resin infiltrant Icon (DMG, Germany).
- Fluoride varnish & Oral hygiene instruction (Type: ACTIVE_COMPARATOR): Oral hygiene instruction and topical fluoridation therapy (Duraphat Fluoride Varnish, Colgate, USA) will be provided.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 3-Month Trial Observation of A1c Change

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type II diabetes mellitus patients at Point Grey Private Hospital~* Trained in self-blood glucose monitoring~* Willingness to test blood glucose levels a minimum of 3 times daily~* Willingness to be trained on IBGMS~Exclusion Criteria:~* Patients with medical conditions that may affect their study participation or results will be excluded.~* Patients currently being treated with steroid medication~* Patients that have impaired liver function

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Internet Intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility